• Home
  • NEW DAY MEDICINE
  • 11 (85) 2025
  • 50 -11 (85) 2025 - Khalimova Kh.M., Rashidova N.S. - RISK FACTORS FOR THE DEVELOPMENT OF NEUROLOGICAL ADVERSE EVENTS AFTER COVID-19 VACCINATION

50 -11 (85) 2025 - Khalimova Kh.M., Rashidova N.S. - RISK FACTORS FOR THE DEVELOPMENT OF NEUROLOGICAL ADVERSE EVENTS AFTER COVID-19 VACCINATION

RISK FACTORS FOR THE DEVELOPMENT OF NEUROLOGICAL ADVERSE EVENTS AFTER COVID-19 VACCINATION

Khalimova Kh.M. - Tashkent State Medical University

Rashidova N.S. - Tashkent State Medical University

Salimjonov J.J. - Tashkent State Medical University

Resume

The study analyzed the clinical and epidemiological characteristics of neurological adverse events following COVID-19 vaccination. It was shown that most neurological complications were mild and reversible. Individuals with a history of previous COVID-19 infection and those with vascular or metabolic comorbidities were more likely to develop post-vaccination neurological manifestations. The findings highlight the importance of careful post-vaccination observation and individualized risk assessment in patients with chronic diseases while confirming the overall safety and effectiveness of COVID-19 vaccines.

Keywords: COVID-19, vaccination, neurological complications, risk factors, arterial hypertension, diabetes mellitus, vaccine safety.

First page

290

Last page

293

For citation:Khalimova Kh.M., Rashidova N.S., Salimjonov J.J. - RISK FACTORS FOR THE DEVELOPMENT OF NEUROLOGICAL ADVERSE EVENTS AFTER COVID-19 VACCINATION//New Day in Medicine 11(85)2025 290-293 https://newdayworldmedicine.com/en/new_day_medicine/11-85-2025

List of References

  1. Всемирная организация здравоохранения. Coronavirus Disease (COVID-19) Dashboard. — WHO, 2023.
  2. Polack F.P., Thomas S.J., Kitchin N. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. // New England Journal of Medicine, 2020;383(27):2603-2615.
  3. Baden L.R., El Sahly H.M., Essink B. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. // New England Journal of Medicine, 2021;384(5):403-416.
  4. Patone M., Handunnetthi L., Saatci D. et al. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. // Nature Medicine, 2021;27:2144-2153.
  5. Khalimova, K.M., Rashidova, N.S. Salimjonov, J.J. Neurological Complications after COVID-19 Vaccination. // Neurosci Behav Physi 54, 540–546 (2024).
  6. Finsterer J. Neurological side effects of SARS-CoV-2 vaccines. — Acta Neurologica Scandinavica, 2023;147(3):198-213.
  7. Hosseini R., Askari N.A., Sadeghi R. Neurological adverse events following COVID-19 vaccination: an updated systematic review. // European Journal of Medical Research, 2023;28(1):47-58.
  8. Chatterjee A., Chakravarty A. Neurological complications following COVID-19 vaccination: a comprehensive review. // Cureus 2022;14(9):e29357.
  9. Censi S., Gandolfi M., Cecchetto C. et al. Risk of Guillain–Barré syndrome after adenoviral vector vaccines against COVID-19: systematic analysis. // European Journal of Neurology, 2024;31(2):233-240.
  10. Chemaitelly H., Ayoub H.H., Tang P. et al. COVID-19 vaccination and the risk of ischemic or hemorrhagic stroke: nationwide cohort study. // International Journal of Infectious Diseases, 2024;139:54-62.
  11. Rafati N., Zarei S., Ghasemi A. Bell’s palsy following COVID-19 vaccination and infection: comparative analysis. // JAMA Otolaryngology Head Neck Surgery, 2023;149(5):437-445.
  12. Faksova K., Maguire G.E.M., Rose-John S. et al. Global Vaccine Data Network analysis of neurological adverse events after COVID-19 vaccination. // Vaccine, 2024;42(3):512-521.
  13. Rose-John S., Neurath M.F. Interleukin-6 trans-signaling in inflammation and disease. // Nature Reviews Immunology, 2023;23(1):21-37.
  14. Papadopoulos C., Kouris A., Themistocleous M. et al. Serum IL-6 and risk of cerebrovascular complications after infection and vaccination. // Stroke, 2022;53(4):1221-1229.
  15. Patterson E., Maguire G.E.M., du Preez H.N. Endothelial glycocalyx degradation and vascular dysfunction in COVID-19 and vaccination. // Frontiers in Medicine, 2022;9:987654.
  16. Liang W., Xu Y., Liu Z. Syndecan-1 as a biomarker of endothelial injury in cerebrovascular disorders. // Frontiers in Neurology, 2023;14:1145789.
  17. Xu Y., Wang S., Zhang L. Prognostic value of Syndecan-1 in patients with ischemic stroke and vascular inflammation. // Acta Neurochirurgica, 2024;166(3):789-797.
  18. Greinacher A., Thiele T., Warkentin T.E. et al. Thrombotic thrombocytopenia after ChAdOx1 nCoV-19 vaccination. // New England Journal of Medicine, 2021;384(22):2092-2101.
  19. Voysey M., Clemens S.A.C., Madhi S.A. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222): interim analysis of four randomized controlled trials. // The Lancet, 2021;397(10269):99-111.
  20. Klein N.P., Lewis N., Goddard K. Surveillance for adverse events after COVID-19 mRNA vaccination. // JAMA, 2022;327(1):39-51.

    file

    download